Loading organizations...
§ Private Profile · Geneve, Geneve, Switzerland
MedTech company developing personalized, non-invasive laser treatment for presbyopia patients, focused on delaying reading glasses.
Kejako, based in Geneva, Switzerland, develops a personalized, non-invasive laser treatment designed to address presbyopia by compensating for visual accommodation decay and delaying the need for reading glasses. The MedTech company employs a proprietary full-eye 3D parametric model with multi-physics simulation to accurately model eye behavior, facilitating early and customized anti-aging ophthalmic treatments for presbyopic patients. Operating in the ophthalmology sector, Kejako is currently in the incubator/accelerator stage, having secured $80K in total funding through grants and accelerator programs. The company's technology was notably featured in a COMSOL Multiphysics story in 2018, highlighting its advanced simulation capabilities. Co-founder Gilles Bos has presented Kejako at industry events such as OIS XIV, with Aurélie Béglé scheduled to present at ESCRS iNovation Day 2026. Kejako was founded in 2015 by David Enfrun and Gilles Bos.
Kejako has raised $810K across 1 funding round.
Kejako has raised $810K in total across 1 funding round.
Kejako has raised $810K across 1 funding round. Most recently, it raised $810K Seed in March 2018.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Mar 21, 2018 | $810K Seed | — | Fongit Seed Invest | Announced |
Kejako has raised $810K in total across 1 funding round.
Kejako's investors include Fongit Seed Invest.